Monopar TherapeuticsMNPR
About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Employees: 16
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,700% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 1
94% more funds holding
Funds holding: 18 [Q4 2024] → 35 (+17) [Q1 2025]
91% more capital invested
Capital invested by funds: $57.1M [Q4 2024] → $109M (+$52.2M) [Q1 2025]
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4.91% more ownership
Funds ownership: 42.41% [Q4 2024] → 47.31% (+4.91%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Sean Lee | 12%upside $40 | Buy Reiterated | 1 Apr 2025 |
Piper Sandler Biren Amin | 114%upside $76 | Overweight Assumed | 19 Mar 2025 |
Financial journalist opinion
Based on 3 articles about MNPR published over the past 30 days









